Henneman John B III
SEC-identified person · CIK 1187572 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Anika Therapeutics, Inc. ANIK | Director | filed 2020–2026 |
| Aprea Therapeutics, Inc. APRE | Director | filed 2019–2026 |
| Orthofix Medical Inc. ofix | Director | filed 2023–2026 |
| R1 RCM Inc. /DE RCM | Director | filed 2022–2024 |
| Seaspine Holdings Corp SPNE | Director | filed 2015–2023 |
| R1 RCM INC. RCM | Director | filed 2016–2022 |
| Newlink Genetics Corp [NLNK] | EVP, Chief Financial Officer | filed 2014–2018 |
| Integra Lifesciences Holdings Corp IART | Exec. VP, CAO and Acting CFO | filed 2006–2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.